P2‐080: Serum glutamine synthetase has no value as a diagnostic biomarker for Alzheimer's disease | Zendy

Vermeiren Yannick | Zendy; Le Bastard Nathalie | Zendy; Clark Christopher | Zendy; Engelborghs Sebastiaan | Zendy; De Deyn Peter | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

P2‐080: Serum glutamine synthetase has no value as a diagnostic biomarker for Alzheimer's disease

Author(s) -

Vermeiren Yannick,

Le Bastard Nathalie,

Clark Christopher,

Engelborghs Sebastiaan,

De Deyn Peter

Publication year - 2011

Publication title -

alzheimer's and dementia

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.713

H-Index - 118

eISSN - 1552-5279

pISSN - 1552-5260

DOI - 10.1016/j.jalz.2011.05.970

Subject(s) - biomarker , medicine , cerebrospinal fluid , disease , lumbar puncture , neurology , glutamine , alzheimer's disease , urine , gastroenterology , psychiatry , biology , biochemistry , amino acid

r value1⁄4 -0.43). Linear combinations of centroid frequency and SNI values based on multivariate modeling accurately tracked ADAS-Cog changes with a highly significant r value of 0.99. Conclusions: It was possible to extract and characterize multiple features of resting-state MEG scans that changed in concert with changes in the ADAS-Cog over the course of 10 months. These results demonstrate the utility of resting-state MEG scans for tracking the progression of AD over periods of less than a year. Additional longitudinal testing of this and additional patient cohorts will support continued improvement of disease severity models based on resting-state MEG.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research